|
|
||||||||


* Laboratory of Immunology and
Laboratory of Molecular and Developmental Biology, National Eye Institute, and
Laboratory of Molecular Immunology, National Institute of Allergy and Infectious Diseases, National Institute of Health, Bethesda, MD 20892
| Abstract |
|---|
|
|
|---|
| Introduction |
|---|
|
|
|---|
The migratory behavior of lymphoid cells is determined by several molecules expressed on their surface, including chemokine receptors and adhesion molecules. A chemokine receptor that plays a major role in the migration of inflammation-inducing Th1 cells is CXCR3 (8, 9, 10). Two major adhesion molecules, which affect migration, are CD49d (VLA-4) and CD62L (L-selectin), with the former being up-regulated and the latter undergoing down-regulation in effector lymphocytes that migrate into nonlymphoid tissues (8, 11, 12, 13, 14).
We have investigated the cells and molecules that participate in immune-mediated inflammation by using an experimental model in which transgenic (Tg) mice expressing hen egg lysozyme (HEL) in their eyes develop ocular inflammation following adoptive transfer of TCR Tg HEL-specific Th1 cells (15, 16). In a previous study (8), we characterized the features of the donor Th1 cells and the remarkable changes in their surface markers during the various stages of their activation in vitro, early migration to lymphoid tissues, and invasion of the target eye. In the present study, we monitored the participation of host cells in the different stages of the inflammatory process. The availability of a clonotypic Ab specific to the TCR of the donor T cells made it possible to differentiate between donor and host cells in the target eyes and secondary lymphoid organs.
We found that the injected donor Th1 cells triggered a sharp increase in the recipients spleen size and cellularity, with the participation of various populations of spleen cells. Similar to donor cells, a significant portion of the host spleen CD4+ T cells was found to undergo changes in their surface markers, which facilitate the migration into nonlymphoid tissues (8). Unlike the rapid influx of donor Th1 cells into the affected eyes, host cells accumulated more slowly, yet eventually became the majority cell population. Different host lymphoid cell populations were identified in the affected eye, including a surprisingly large number of CD11c dendritic cells (DCs). Interestingly, the surface marker profile of the eye-infiltrating CD4 host cells differed from that of the corresponding populations located in the spleen or blood by exhibiting a profile shift toward that of activated T cells.
| Materials and Methods |
|---|
|
|
|---|
HEL-Tg mice, expressing membrane-bound HEL under control of the
A-crystallin promoter, on the FVB/N background, were generated as described previously (17). HEL-specific TCR Tg mice, on the B10.BR background, designated "3A9" (18), were a gift from M. Davis (Stanford University, Stanford, CA). Tg mice from each of the two lines were mated to produce (FVB/N x B10.BR)F1 hybrids, expressing either HEL in their eyes, or the 3A9 TCR on their T cells. The mice expressing HEL in their eyes are designated here "HEL-Tg," whereas those expressing 3A9 TCR are named 3A9. Only such F1 hybrid mice of the two lines were used in the present study. In all adoptive transfer experiments the cells used were from 3A9 donors, whereas recipients were HEL-Tg mice. The mice were housed in a pathogen-free facility, and all manipulations were performed in compliance with the National Institutes of Health Resolution on the Use of Animals in Research.
Generation of HEL-specific Th1 lymphocytes
Th1 cells were prepared as described in detail elsewhere (15, 16). Briefly, purified CD4 cells (>95%) from 3A9 mice were incubated for 3 days with HEL (at 2 µg/ml) and irradiated (30 Gy) syngeneic wild-type naive spleen cells, serving as APC, in Th1 polarizing conditions (IL-12 and anti-IL-4 Ab (15, 16)). Following ensuing incubation with IL-2 for 4 days, polarized Th1 cells were stimulated again with HEL, APC, and the Th1 polarization mixture to produce the reactivated cell preparation, which is highly pathogenic (8). The Th1 cell polarization was qualified by assessment of intracellular cytokines and cytokine production by these cells, as detailed elsewhere (15); Th1 cell suspensions produced high levels of IFN-
, but almost no IL-4, expressed strongly surface IL-18R, but little of the T1/ST2 marker.
Induction of ocular inflammation by adoptive transfer of HEL-specific Th1 lymphocytes
Reactivated Th1 cells (2 x 106, 5 x 106, or 10 x 106, as indicated) were injected in a volume of 0.2 ml via the tail vein into naive HEL-Tg mice to induce ocular inflammation. Recipient mice were sacrificed at different time points following cell transfer, as indicated. Blood, spleen, and eyes of recipient mice were collected and prepared for flow cytometric (FCM) analysis.
FCM analysis of surface marker expression
Abs were conjugated with FITC, PE, PerCP, or allophycocyanin (ALPC), as indicated. mAbs against CD4 (PE or ALPC), CD8 (PE), CD19 (PerCP), CD11c (ALPC), CD49d (PE), CD62L (PE), CD69 (PE), and CD25 (PE) were purchased from BD Pharmingen. Rabbit anti-CXCR3 Ab was obtained from Zymed Laboratories, whereas goat anti-rabbit IgG Ab (PE) was from Southern Biotechnology Associates. A clonotypic mAb specific for the Tg TCR of the 3A9 mice, designated 1G12, a gift from E. Unanue (Washington University, St. Louis, MO), was used conjugated with FITC. Control staining was performed using the following isotype Abs: rat IgG 2a,
(ALPC), rat IgG1,
(PE), rat IgG2b,
(PE), mouse IgG1 (FITC), hamster IgG1,
(PE) (all obtained from BD Pharmingen), and rabbit IgG (Pierce). Anti-CD16/CD32 (BD Pharmingen) was used to block FcRs in all the stainings.
Blood, spleen, and eyes of recipient mice were collected at different time points following adoptive transfer of Th1 cells. Single-cell suspensions of blood and spleen cells were prepared by conventional methods. Eyes were dissected and then digested in RPMI 1640 medium containing 10% FBS and 1 mg/ml collagenase (Sigma-Aldrich) for 2 h at 37°C. Collected cells were filtered through a cell strainer, followed by RBC lysis with ACK buffer and washing in FACS buffer. FCM analysis was performed on a FACSCalibur (BD Biosciences). One million events were acquired for cell samples recovered from spleen or blood of recipient mice, whereas all cells collected from recipient eyes (below 106 events) were analyzed.
BrdU incorporation assay
HEL-Tg recipient mice of reactivated Th1 3A9 cells (5 x 106) were injected i.p., on day 6 postcell transfer, with 0.5 mg of BrdU (BD Pharmingen). Recipient mice were euthanized 4 h later, and the infiltrating cells in their eyes were collected and stained with PE-conjugated CD4 Ab and biotin-conjugated 1G12 Ab, plus streptavidin (SA)-APC (BD Pharmingen). Cells were then fixed and permeabilized using BD Cytofix/Cytoperm buffer (BrdU Flow Kit; BD Pharmingen), stored overnight, and then stained with FITC-conjugated anti-BrdU Ab (BD Pharmingen). Gated CD4 cells were then analyzed by FCM for BrdU incorporation.
Immunofluorscence staining of eye tissues
Eyes were removed from mice 4 days after T cell transfer and frozen in OCT-embedding medium (Sakura Finetek). Frozen sections (8-µm thick) were fixed in acetone at 20°C, and immunofluorescence was performed using the tyramide amplification method (TSA-Direct kit; Molecular Probe-Invitrogen Life Technologies). Frozen sections were blocked with blocking buffer (TSA-Direct kit), and endogenous peroxidase activity was quenched with peroxidase-quenching reagent (DakoCytomation) for 10 min at room temperature. A total of 0.5 µg/ml purified anti-CD11c (clone N418; eBioscience) and 0.5 µg/ml biotinylated anti-CD4 (clone RM4-5; eBioscience) was applied for 1 h at room temperature. Slides were washed and incubated with SA-HRP for 30 min. Biotinylated anti-CD4 was detected with Tyramide-Alexa Fluor 594 (TSA-Direct kit). Next, HRP activity was quenched with peroxidase-quenching reagent (DakoCytomation) for 10 min, and biotin sites blocked with excess unlabeled avidin and biotin (Avidin/Biotin blocking kit). The sections were then incubated with biotinylated-goat anti-hamster IgG (Jackson ImmunoResearch Laboratories). Slides were washed and incubated with SA-HRP conjugate (TSA-Direct kit). Staining by hamster anti-CD11c was visualized by amplification of the signal with Tyramide-Alexa Fluor 488 (TSA-Direct kit). Slides were mounted with Flouromount G (Southern Biotechnology Associates) and were analyzed by fluorescence microscopy (Axioplan 2; Carl Zeiss).
Statistical analysis
Students t test was used to determine the significance of differences between the means of different groups.
| Results |
|---|
|
|
|---|
Groups of HEL-Tg mice were injected with either naive CD4 or reactivated Th1 3A9 cells, and the recipients spleens were collected at different time points. A pronounced increase in the spleen size of recipient mice injected with 210 x 106 reactivated Th1 cells was regularly observed (Fig. 1A). This phenomenon of increase in spleen size was similarly observed in wild-type recipients, indicating that HEL expression by the Tg recipient mouse does not participate in the biological process (data not shown). The increase in size began on day 2, reached a peak around day 4, and was followed by a gradual decline thereafter (Fig. 1B).
|
400,000 at their peak on day 4 in the experiments presented in Fig. 1E, in which 2 x 106 reactivated Th1 cells were injected. FCM analysis on days 0, 2, 4, and 7 following cell transfer was also performed with Abs against different cell surface markers (Fig. 1E). This analysis showed that most nucleated cells collected from the recipient spleens expressed CD45. An increase in the absolute number of CD45+ cells was seen in these spleens on day 2 postcell injection, reaching a peak of >200 million cells (approximately twice the number of cells in untreated mice) on day 4 and decreasing on day 7 (Fig. 1E). The other populations of host leukocytes measured at the different time points following injection of the reactivated 3A9 Th1 cells included CD4 and CD8 T cells, B cells (CD19), granulocytes (GR-1), and DCs (CD11c) (Fig. 1E). Four of the five populations exhibited similar increases in their peak number, to approximately double their numbers on day 0. The only population that had a larger increase in cell number was that of CD11c+, which more than tripled in size. The CD11c+ population also differed from the other populations in its kinetics, reaching a peak on day 2, whereas all other populations reached their peak on day 4. In contrast to the observations in recipients of reactivated Th1 cells, no changes in the numbers of either donor or recipient cells were found in the spleen of recipients of naive 3A9 CD4 cells throughout the tested time period (Fig. 1A and data not shown).
Taken together, these results demonstrate an expansion of host lymphoid cells in the spleens of recipient mice injected with reactivated Th1 cells. This expansion is presumably triggered by the adoptively transferred reactivated lymphocytes.
Phenotype changes on host CD4+ lymphocytes in spleen and blood of recipient mice
To determine the expression of function-related surface markers on host CD4+ lymphocytes in recipient mice, we conducted FCM analysis with Abs against two activation markers, CD25 and CD69 (19, 20), and three molecules that determine to a large extent the migratory properties of T lymphocytes, i.e., the chemokine receptor CXCR3 (8, 9, 10) and the adhesion molecules CD49d (VLA-4) (8, 11, 12) and CD62L (L-selectin) (8, 13, 14). Fig. 2 summarizes the data obtained in four experiments with spleen and blood cells of recipients of naive CD4 or reactivated Th1 cells from 3A9 donors. There was little change in the expression of any of the surface molecules on host CD4+ cells from recipients of naive CD4 cells throughout the 7-day period of the experiments. In contrast, notable changes were observed on host spleen and blood CD4+ cells of recipients of reactivated Th1 cells. The percentage of cells expressing CD25 and CD69 was moderately higher in recipients of the reactivated cells than in recipients of naive CD4 cells on days 2 and 4 postcell injection, but declined to the baseline level on day 7. The proportions of host CD4 cells expressing CXCR3 and CD49d in recipients of the reactivated Th1 cells were similar on day 2 to that of the control, i.e.,
10%, but these proportions increased sharply on day 4 to
3040%, with little or no additional change by day 7. Furthermore, the expression of CD62L on these host cells declined from its baseline high level of 8090% on day 2 to 5070% on day 4, with a partial rebound on day 7.
|
Migration of host lymphoid cells into the recipients eyes
Eyes of recipients of reactivated Th1 cells developed severe inflammatory reactions characterized by infiltration of lymphoid cells into multiple ocular tissues (Fig. 3A). To identify the infiltrating cells and to monitor the pattern of their migration, we extracted cells from affected eyes by collagenase treatment at different time points postcell transfer and identified them by FCM. Donor and host cells were identified by their positive or negative staining with the clonotypic 1G12 Ab, respectively, and the different lymphoid cell populations were identified by their specific cell markers. In line with our previous study (8), massive invasion of donor CD4+ T cells (1G12+) was observed on day 4 postcell injection, but these cells were outnumbered by host CD4+ T cells (1G12) on day 7 (Fig. 3B).
|
9,000 per eye recorded for each of these T cell populations on day 7. Host B cells (CD19) were also seen among the infiltrating cells, but at low numbers (
600/eye). In contrast, considerable numbers of granulocytes (GR-1) were recruited into the inflamed eye, with the peak of
5,000/eye reached on day 4 and a steep decline thereafter.
Of particular interest is the participation of CD11c+ DCs in the inflammatory process. By FCM, substantial numbers of CD11c+ cells migrated rapidly into the affected eyes, reaching a peak of
7,000 per eye on day 4 and declining slightly on day 7 (Fig. 3C). In addition, analysis by immunofluorescence staining of eye tissue at day 4 demonstrated the presence of CD11c+CD4 DCs in eye tissues (Fig. 4). DCs were clustered with CD4+ T cells in the retina, particularly in regions near the optic nerve, as well as at the limbus area, the two loci that are the entry points for the infiltrating cells in these eyes (15).
|
Phenotypic changes on the host CD4+ lymphocytes infiltrating into the target eye
To examine the expression of function-related surface markers on tissue-infiltrating host CD4 lymphocytes, we analyzed by FCM the CD4+1G12 population collected from the inflamed eyes on day 7 postcell injection, as well as the corresponding cell population in the spleen and blood of the same recipient mice (Fig. 5). In accord with the data recorded above (Fig. 2), similar profiles are seen with the spleen and blood lymphocytes. In contrast, remarkable differences were found between cells from these lymphoid organs and the eye-infiltrating lymphocytes. Thus, the expression of the two activation markers, CD25 and CD69, as well as of the adhesion molecule CD49d was higher on host CD4 cells collected from inflamed eyes than on the corresponding cells from spleen or blood. In contrast, expression of the chemokine receptor CXCR3 and the adhesion molecule CD62L was lower on eye-infiltrating cells than on spleen or blood cells.
|
Cell proliferation in the inflamed eye
Lymphocyte activation may bring about cellular proliferation. To examine the proliferative activity of infiltrating cells in recipient mouse eyes we used the BrdU assay. Cells collected from inflamed eyes of recipient mice, on day 6 postcell transfer and after a 4-h pulse in vivo with BrdU, were analyzed by FCM for BrdU incorporation. As seen in Fig. 6, BrdU incorporation was found in small fractions of both host and donor cells, indicating proliferation in these positive cells.
|
| Discussion |
|---|
|
|
|---|
It is possible that minute amounts of HEL are carried over into the recipient mice along with the transferred Th1 cells, but apparently they have no effect on the immune response of the recipient mice. In experiments not shown here, naive wild-type CD4 cells were cultured with HEL, using the same procedure used for reactivation of Th1 cells. Injection of 5 x 106 of these wild-type CD4 cells into HEL-Tg mice did not induce any increase in spleen size or ocular inflammation. Furthermore, no immune response against HEL could be detected in the recipient mice by the lymphocyte proliferation or Ab assays. Moreover, these negative results are in line with a previous study (17) in which we showed that HEL Tg mice develop immunotolerance to HEL, apparently due to HEL expression in thymi of these mice. Another finding of interest concerns the effect of the transferred Th1 cells on the profile of surface molecules on host spleen CD4 lymphocytes (Fig. 2); to the best of our knowledge, the present study is the first to record such data. Particularly important is the up-regulation of CXCR3 and CD49d, as well as the down-regulation of CD62L on a large portion of these host cells. These combined changes in surface molecules are known to prepare T lymphocytes for migration into nonlymphoid tissues (8, 9, 10, 11, 12, 13, 14), and it is conceivable that many of the host cells acquiring the new phenotype are those that migrate from the spleen into inflammation sites, the eye in this study. Indeed, the profile of these modified host cells is very similar to that of the donor CD4 cells before their migration from the recipients spleen to their eyes (8). This notion about the migration of CXCR3+ cells into inflamed tissues also agrees with our previous observation of high levels of CXCR3 ligands (monokine-induced by IFN-
/CXCL9 and IFN-
-inducible protein-10/CXCL10) in the target mouse eyes (16).
Using FCM analysis of the eye-infiltrating cells, we monitored quantitatively, for the first time, the participation of the major host cell populations in the inflammatory process in the affected eye (Fig. 3). The availability of the clonotypic Ab, 1G12, which identifies the donor cells, made it possible to differentiate between donor and host CD4 cells. Notably, the migration kinetics of host T lymphocytes differed from that of the donor cells. The massive migration of T lymphocytes into the eye consisted mainly of donor cells on day 4, but the number of these cells declined slightly on day 7, when the great majority of T cells were from the host (Fig. 3). The total number of infiltrating cells was also higher on day 7 than on day 4. Thus, our analysis of the cellular infiltrate provides quantitative support to the notion that at the peak of the inflammatory process, the majority of lymphocytes at a tissue-localized inflammation are recruited cells, with no specificity toward the target Ag (1, 2).
Large numbers of DCs were found in the affected recipient eyes. It is possible that these cells were recruited from the peripheral blood by chemokines such as MIP3
/CCL20, released from nonimmune tissue cells, similar to the observations made with models of inflammatory bowel disease (24) or pulmonary inflammation (22, 25). DCs migrated to the target eye before the host B or T cells, reaching a peak on day 4 and declining slightly on day 7. The function of these DCs in the inflammation process is not yet clear; however, there are several possible implications of these findings. For example, DCs within the eye may present HEL to donor T cells, resulting in the activation of these T cells (8). In addition, DCs may be involved in recruitment of lymphocytes into the eye, by releasing chemokine ligands of CXCR3 or CCR5, such as CXCL911, or CCL35, which act to attract Th1 cells into tissues (26).
Another noteworthy observation of this study is the difference between the profiles of surface markers of the host CD4 cells in the spleen or blood and in the inflamed eyes (Fig. 5). Particularly interesting is the finding of lower expression levels of CXCR3 (13 vs 31%) and the higher levels of CD25 and CD69 on the host-infiltrating cells than on the corresponding spleen cells (50 and 29% vs 15 and 18%, respectively). This change in the surface marker profile on host CD4 cells is similar to, albeit less pronounced than, that we observed with the eye-infiltrating donor cells (8). In that study, the expression of CXCR3 declined from 88% on spleen cells to 11% on the eye-infiltrating cells, whereas the expression of CD25 and CD69 was 5 and 7% on spleen cells and 40 and 40% on infiltrating cells, respectively (8). The finding of a profile change on eye-infiltrating donor cells also resembles the observation with T cells that induce EAU (7), or those that invade the CNS and induce EAE (5). The surface marker profile of the tissue-infiltrating T cells resembles that of activated cells, and the change in these markers seen in these cited studies was attributed to the reactivation of disease-inducing T cells following their exposure to the specific Ags in the target tissue (5, 7, 8). This mechanism cannot be applied, however, to the host cells that do not recognize HEL in our system. We suggest, therefore, that the profile change of the host CD4 cells is a result of cytokines that are released by the donor cells and affect the recruited host cells. This consequent shift in surface profile is less potent than the actual activation, and, indeed, as mentioned above, the level of profile change on the host CD4 cells is markedly lower than that we observed on donor cells.
In summary, we describe in this study for the first time in detail the active involvement of host cells in the adoptively transferred Th1-mediated tissue inflammation, as well as the features of the participating cells. The transferred cells initiated spleen enlargement, as well as remarkable changes in the surface marker profile on host lymphocytes. Analysis of the recruitment process into the target tissue revealed involvement of various host cell populations, with changes of the cell surface marker profile following the migration into the target tissue. We propose that the new information on host cells in this experimental system could be applied to the population of Ag-nonspecific lymphocytes that are recruited into immune-mediated inflammatory sites.
| Acknowledgments |
|---|
| Disclosures |
|---|
|
|
|---|
| Footnotes |
|---|
1 This research was supported by the Intramural Research Program of the National Eye Institute, National Institutes of Health. ![]()
2 Address correspondence and reprint requests to Dr. Igal Gery, Laboratory of Immunology, National Eye Institute, National Institutes of Health, Building 10, Room 10N112, Bethesda, MD 20892-1857. E-mail address: geryi{at}nei.nih.gov ![]()
3 Abbreviations used in this paper: EAE, experimental autoimmune encephalitis; EAU, experimental autoimmune uveoretinitis; Tg, transgenic; HEL, hen egg lysozyme; DC, dendritic cell; FCM, flow cytometric; ALPC, allophycocyanin; SA, streptavidin. ![]()
Received for publication June 10, 2005. Accepted for publication June 14, 2006.
| References |
|---|
|
|
|---|
4 integrin and its ligand VCAM-1 in the specific extravasation of a tumor-specific TH2 clone into tumor tissue that initiates its rejection. Int. J. Cancer 111: 558-567. [Medline]This article has been cited by other articles:
![]() |
G. Shi, C. A. Cox, B. P. Vistica, C. Tan, E. F. Wawrousek, and I. Gery Phenotype Switching by Inflammation-Inducing Polarized Th17 Cells, but Not by Th1 Cells J. Immunol., November 15, 2008; 181(10): 7205 - 7213. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. A. Cox, G. Shi, H. Yin, B. P. Vistica, E. F. Wawrousek, C.-C. Chan, and I. Gery Both Th1 and Th17 Are Immunopathogenic but Differ in Other Key Biological Activities J. Immunol., June 1, 2008; 180(11): 7414 - 7422. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Kwun, H. Hu, E. Schadde, D. Roenneburg, K. A. Sullivan, J. DeMartino, W. J. Burlingham, and S. J. Knechtle Altered Distribution of H60 Minor H Antigen-Specific CD8 T Cells and Attenuated Chronic Vasculopathy in Minor Histocompatibility Antigen Mismatched Heart Transplantation in Cxcr3 / Mouse Recipients J. Immunol., December 15, 2007; 179(12): 8016 - 8025. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |